Patents Assigned to Biotica Technology Limited
-
Patent number: 8008318Abstract: The present invention relates to 39-desmethoxyrapamycin derivatives and their uses thereof. The present invention provides for the use of these compounds in the treatment of cancer and/or B-cell malignancies, the induction or maintenance of immunosuppression, the treatment of transplantation rejection, graft vs. host disease, autoimmune disorders, diseases of inflammation, vascular disease and fibrotic diseases, the stimulation of neuronal regeneration or the treatment of fungal infections.Type: GrantFiled: December 3, 2009Date of Patent: August 30, 2011Assignee: Biotica Technology LimitedInventors: Christoph Hendrik Beckmann, Steven James Moss, Rose Mary Sheridan, Mingqiang Zhang, Barrie Wilkinson
-
Patent number: 7897608Abstract: The present invention relates to novel 39-desmethoxy-39-methylrapamycin derivatives, methods for their production, and uses thereof. In a further aspect the present invention provides for the use of these 39-desmethoxy-39 -methylrapamycin derivatives in the treatment of cancer and/or B-cell malignancies, the induction or maintenance of immunosuppression, the treatment of transplantation rejection, graft vs. host disease, autoimmune disorders, diseases of inflammation, vascular disease and fibrotic diseases, the stimulation of neuronal regeneration or the treatment of fungal infections.Type: GrantFiled: November 19, 2008Date of Patent: March 1, 2011Assignee: Biotica Technology LimitedInventors: Barrie Wilkinson, Mingqiang Zhang, Rose Mary Sheridan
-
Patent number: 7807800Abstract: 14-membered macrolide compounds such as erythromycins are provided with functional groups at the 14- and/or 15-position by providing a 14-membered aglycone template and feeding it to a strain capable of hydroxylating it at the 14 and/or 15 position. The strain may be found by screening, selected from known strains (e.g. Streptomyces eurythermus DSM 40014) or produced by genetically engineering a strain to express a cytochrome P450 enzyme.Type: GrantFiled: November 29, 2004Date of Patent: October 5, 2010Assignee: Biotica Technology LimitedInventors: Steven Gary Kendrew, Rachel E. Lill
-
Patent number: 7807418Abstract: A hybrid type I polyketide synthase gene typically containing a starter module and a plurality of heterologous extender modules is used to synthesise novel polyketides. It is preferably under the control of type II polypolyketide synthase promoter e.g. act I or S. coelicolor.Type: GrantFiled: July 12, 2004Date of Patent: October 5, 2010Assignee: Biotica Technology LimitedInventors: Peter Francis Leadlay, James Staunton, Jesus Cortes
-
Publication number: 20100081682Abstract: The present invention relates to 39-desmethoxyrapamycin derivatives and their uses thereof. The present invention provides for the use of these compounds in the treatment of cancer and/or B-cell malignancies, the induction or maintenance of immunosuppression, the treatment of transplantation rejection, graft vs. host disease, autoimmune disorders, diseases of inflammation, vascular disease and fibrotic diseases, the stimulation of neuronal regeneration or the treatment of fungal infections.Type: ApplicationFiled: December 3, 2009Publication date: April 1, 2010Applicant: Biotica Technology LimitedInventors: Christoph Hendrik Beckmann, Steven James Moss, Rose Mary Sheridan, Mingqiang Zhang, Barrie Wilkinson
-
Patent number: 7655673Abstract: The present invention relates to medical uses of 39-desmethoxyrapamycin.Type: GrantFiled: January 10, 2007Date of Patent: February 2, 2010Assignee: Biotica Technology LimitedInventors: Mingqiang Zhang, Rose Mary Sheridan
-
Patent number: 7648996Abstract: The present invention relates to novel 39-desmethoxyrapamycin derivatives, methods for their production, and uses thereof. In a further aspect the present invention provides for the use of these 39-desmethoxyrapamycin derivatives in the treatment of cancer and/or B-cell malignancies, the induction or maintenance of immunosuppression, the treatment of transplantation rejection, graft vs. host disease, autoimmune disorders, diseases of inflammation, vascular disease and fibrotic diseases, the stimulation of neuronal regeneration or the treatment of fungal infections.Type: GrantFiled: March 10, 2006Date of Patent: January 19, 2010Assignee: Biotica Technology LimitedInventors: Christoph Hendrik Beckmann, Steven James Moss, Rose Mary Sheridan, Mingqiang Zhang, Barrie Wilkinson
-
Patent number: 7595175Abstract: Biosyntheses of compounds whereof at least portions are polyketides produced by means of polyketide synthase (PKS) enzyme complexes are carried out after specific alterations have been made within the acyltransferase (AT) domains of the PKSs. Particular motifs in or near the substrate binding pocket are disclosed, such that alterations therein affect substrate specificity.Type: GrantFiled: August 14, 2001Date of Patent: September 29, 2009Assignee: Biotica Technology LimitedInventors: Hrvoje Petkovic, Steven Gary Kendrew, Peter Francis Leadlay
-
Publication number: 20090209572Abstract: The present invention relates to novel 36-des(3-methoxy-4-hydroxycyclohexyl)-36-(3-hydroxycycloheptyl)rapamycin derivatives, methods for their production, and uses thereof. In a further aspect the present invention provides for the use of these 36-des(3-methoxy-4-hydroxycyclohexyl)-36-(3-hydroxycycloheptyl)rapamycin derivatives in the treatment of cancer and/or B-cell malignancies, the induction or maintenance of immunosuppression, the treatment of transplantation rejection, graft vs. host disease, autoimmune disorders, diseases of inflammation, vascular disease and fibrotic diseases, the stimulation of neuronal regeneration or the treatment of fungal infections.Type: ApplicationFiled: November 19, 2008Publication date: August 20, 2009Applicant: Biotica Technology LimitedInventors: Barrie Wilkinson, Ming-Qiang Zhang, Rose Mary Sheridan, Christoph Beckmann
-
Patent number: 7560252Abstract: The present invention relates to the biosynthesis of polyketides and derives from the cloning of nucleic acids encoding a polyketide synthase and other associated proteins involved in the synthesis of the polyketide borrelidin. Materials and methods including enzyme systems, nucleic acids, vectors and cells are provided for the preparation of polyketides including borrelidin and analogues and derivatives thereof. Novel polyketide molecules are also provided.Type: GrantFiled: December 24, 2003Date of Patent: July 14, 2009Assignees: Biotica Technology Limited, The University of OviedoInventors: Jose A Salas, Carmen Mendez, Carlos Olano, Cesar Sanchez, Alfredo F Brana, Barrie Wilkinson, Christine J Martin, Steven Moss, Peter F Leadlay, Marko Oliynyk
-
Publication number: 20090176819Abstract: The present invention relates to novel 39-desmethoxy-39-methylrapamycin derivatives, methods for their production, and uses thereof. In a further aspect the present invention provides for the use of these 39-desmethoxy-39-methylrapamycin derivatives in the treatment of cancer and/or B-cell malignancies, the induction or maintenance of immunosuppression, the treatment of transplantation rejection, graft vs. host disease, autoimmune disorders, diseases of inflammation, vascular disease and fibrotic diseases, the stimulation of neuronal regeneration or the treatment of fungal infections.Type: ApplicationFiled: November 19, 2008Publication date: July 9, 2009Applicants: Wyeth, Biotica Technology LimitedInventors: Barrie Wilkinson, Ming-Qiang Zhang, Rose Mary Sheridan
-
Patent number: 7482137Abstract: The present invention relates to hybrid glycosylated products, and in particular, to natural products such as polyketides and glycopeptides, and to processes for their preparation. The invention is particularly concerned with recombinant cells in which a cloned microbial glycosyltransferase can be conveniently screened for its ability to generate specific glycosylated derivatives when supplied with polyketide, peptide, or polyketide-peptides as substrates. The invention demonstrates that cloned glycosyltransferases when rapidly screened for their ability to attach a range of activated sugars to a range of exogenously supplied or endogenously generated aglycone templates, show a surprising flexibility towards both aglycone and sugar substrates, and that this process allows the production of glycosylated polyketides in good yield.Type: GrantFiled: October 12, 2006Date of Patent: January 27, 2009Assignee: Biotica Technology LimitedInventors: Peter Francis Leadlay, James Staunton, Sabine Gaisser
-
Patent number: 7390895Abstract: The present invention relates to production of polyketides and other natural products and to libraries of compounds and individual novel compounds. One important area is the isolation and potential use of novel FKBP-ligand analogues and host cells that produce these compounds. The invention is particularly concerned with methods for the efficient transformation of strains that produce FKBP analogues and recombinant cells in which cloned genes or gene cassettes are expressed to generate novel compounds such as polyketide (especially rapamycin) FKBP-ligand analogues, and to processes for their preparation, and to means employed therein (e.g. nucleic acids, vectors, gene cassettes and genetically modified strains).Type: GrantFiled: July 16, 2007Date of Patent: June 24, 2008Assignee: Biotica Technology LimitedInventors: Matthew Alan Gregory, Sabine Gaisser, Hrvoje Petkovic, Steven Moss
-
Patent number: 7381546Abstract: The rapamycin gene cluster is an example of a gene cluster which includes a gene (rapL) leading to the formation of a precursor compound (pipecolic acid, in this case) which is required for inclusion in the larger product (rapamycin) produced by the enzymes encoded by the cluster. We have produced a mutant strain containing a rapamycin gene cluster in which the rapL gene is disabled. The strain does not naturally produce rapamycin but does so if fed with pipecolic acid. By feeding with alternative carboxylic acids we have produced variants of rapamycins. Tests have shown biological activity.Type: GrantFiled: January 10, 2006Date of Patent: June 3, 2008Assignee: Biotica Technology LimitedInventors: Peter Francis Leadlay, James Staunton, Lake Ee Khaw
-
Patent number: 7300942Abstract: The present invention relates to production of polyketides and other natural products and to libraries of compounds and individual novel compounds. One important area is the isolation and potential use of novel FKBP-ligand analogues and host cells that produce these compounds. The invention is particularly concerned with methods for the efficient transformation of strains that produce FKBP analogues and recombinant cells in which cloned genes or gene cassettes are expressed to generate novel compounds such as polyketide (especially rapamycin) FKBP-ligand analogues, and to processes for their,preparation, and to means employed therein (e.g. nucleic acids, vectors, gene cassettes and genetically modified strains).Type: GrantFiled: July 16, 2003Date of Patent: November 27, 2007Assignee: Biotica Technology LimitedInventors: Matthew Alan Gregory, Sabine Gaisser, Hrvoje Petkovic, Steven Moss
-
Patent number: 7198922Abstract: A polyketide synthase (“PKS”) of Type I is a complex multienzyme including a loading domain linked to a multiplicity of extension domains. The first extension module receives an acyl starter unit from the loading domain and each extension module adds a further ketide unit which may undergo processing (e.g. reduction). We have found that the Ksq domain possessed by some PKS's has decarboxylating activity, e.g. generating (substituted) acyl from (substituted) malonyl. The CLF domain of type II PKS's has similar activity. By inserting loading modules including such domains into PKS's not normally possessing them it is possible to control the starter units used.Type: GrantFiled: February 19, 2004Date of Patent: April 3, 2007Assignees: Biotica Technology Limited, Pfizer, Inc.Inventors: Peter Francis Leadlay, James Staunton, Jesus Cortes, Hamish Alastair Irvine McArthur
-
Patent number: 7183289Abstract: The present invention relates to medical uses of 39-desmethoxyrapamycin.Type: GrantFiled: April 1, 2005Date of Patent: February 27, 2007Assignee: Biotica Technology LimitedInventors: Mingqiang Zhang, Rose Mary Sheridan
-
Patent number: 7148045Abstract: A polyketide synthase (“PKS”) of Type I is a complex multienzyme including a loading domain linked to a multiplicity of extension domains. The first extension module receives an acyl starter unit from the loading domain and each extension module adds a further ketide unit which may undergo processing (e.g. reduction). We have found that the Ksq domain possessed by some PKS's has decarboxylating activity, e.g. generating (substituted) acyl from (substituted) malonyl. The CLF domain of type II PKS's has similar activity. By inserting loading modules including such domains into PKS's not normally possessing them it is possible to control the starter units used.Type: GrantFiled: June 29, 1999Date of Patent: December 12, 2006Assignee: Biotica Technology LimitedInventors: Peter Francis Leadlay, James Staunton, Jesus Cortes, Hamish Alastair Irvine McArthur
-
Patent number: 7018808Abstract: The rapamycin gene cluster is an example of a gene cluster which includes a gene (rapL) leading to the formation of a precursor compound (pipecolic acid, in this case) which is required for inclusion in the larger product (rapamycin) produced by the enzymes encoded by the cluster. We have produced a mutant strain containing a rapamycin gene cluster in which the rapL gene is disabled. The strain does not naturally produce rapamycin but does so if fed with pipecolic acid. By feeding with alternative carboxylic acids we have produced variants of rapamycins. Tests have shown biological activity.Type: GrantFiled: December 2, 2002Date of Patent: March 28, 2006Assignee: Biotica Technology LimitedInventors: Peter Francis Leadlay, James Staunton, Lake Ee Khaw
-
Patent number: 7001747Abstract: Nucleic acid molecules encoding at least part of a Type I polyketide synthase, and having a polylinker with multiple restriction enzyme sites in place of one or more PKS genes encoding enzymes associated with reduction, optionally further including nucleic acid incorporated into the polylinker, the further nucleic acid encoding one or more reductive enzymes; plasmids incorporating such nucleic acids; host cells transfected with such plasmids; methods relating thereto.Type: GrantFiled: July 6, 1999Date of Patent: February 21, 2006Assignees: Biotica Technology Limited, Pfizer, Inc.Inventors: Johannes Kellenberger, Peter Francis Leadlay, James Staunton, Kim Jonelle Stutzman-Engwall, Hamish Alastair Irvine McArthur